Literature DB >> 34918239

Progress in the Development of Structure-Based Vaccines.

Sunil Thomas1, Ann Abraham2.   

Abstract

The immune response elicited by vaccines against microorganisms makes it the most successful medical interventions against infectious diseases. Conventional vaccines have limitations in inducing immunity against many types of pathogenic microorganism. The genetic diversity of microorganisms, coupled with the high degree of sequence variability in antigenic proteins, presents a challenge to developing broadly effective conventional vaccines. Atomic-resolution structure determination is crucial for understanding antigenic protein function. Cryo-electron microscopy, nuclear magnetic resonance spectroscopy coupled with bioinformatics provide three-dimensional structure of the antigenic proteins and provide a wealth of information about the organization of individual atoms and their chemical makeup. The atomic detail information of proteins offers enormous potential to rationally engineer proteins to enhance their properties and act as effective immunogens to induce immunity. The observation that whole protein antigens are not necessarily essential for inducing immunity has led to the emergence "structural vaccinology." Structure-based vaccines are designed on the rationale that protective epitopes should be sufficient to induce immune responses and provide protection against pathogens. In 2013 we published a review on structure-based vaccines (Thomas and Luxon. Expert Rev Vaccines 12 1301-11, 2013). This review states the progress in development of structure-based vaccines since the first review.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antigen; Epitope; Structural biology; Structure-based vaccines

Mesh:

Substances:

Year:  2022        PMID: 34918239     DOI: 10.1007/978-1-0716-1892-9_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  40 in total

Review 1.  Vaccines based on structure-based design provide protection against infectious diseases.

Authors:  Sunil Thomas; Bruce A Luxon
Journal:  Expert Rev Vaccines       Date:  2013-10-04       Impact factor: 5.217

Review 2.  Antibody-guided structure-based vaccines.

Authors:  Peter D Kwong; Brandon J DeKosky; Jeffrey B Ulmer
Journal:  Semin Immunol       Date:  2020-11-24       Impact factor: 11.130

3.  Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.

Authors:  Gwo-Yu Chuang; Hui Geng; Marie Pancera; Kai Xu; Cheng Cheng; Priyamvada Acharya; Michael Chambers; Aliaksandr Druz; Yaroslav Tsybovsky; Timothy G Wanninger; Yongping Yang; Nicole A Doria-Rose; Ivelin S Georgiev; Jason Gorman; M Gordon Joyce; Sijy O'Dell; Tongqing Zhou; Adrian B McDermott; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 4.  Structure-Based Vaccine Antigen Design.

Authors:  Barney S Graham; Morgan S A Gilman; Jason S McLellan
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

5.  Monozygotic twins of different sex.

Authors:  J H Edwards; T Dent; J Kahn
Journal:  J Med Genet       Date:  1966-06       Impact factor: 6.318

6.  A proof of concept for structure-based vaccine design targeting RSV in humans.

Authors:  Michelle C Crank; Tracy J Ruckwardt; Man Chen; Kaitlyn M Morabito; Emily Phung; Pamela J Costner; LaSonji A Holman; Somia P Hickman; Nina M Berkowitz; Ingelise J Gordon; Galina V Yamshchikov; Martin R Gaudinski; Azad Kumar; Lauren A Chang; Syed M Moin; Juliane P Hill; Anthony T DiPiazza; Richard M Schwartz; Lisa Kueltzo; Jonathan W Cooper; Peifeng Chen; Judith A Stein; Kevin Carlton; Jason G Gall; Martha C Nason; Peter D Kwong; Grace L Chen; John R Mascola; Jason S McLellan; Julie E Ledgerwood; Barney S Graham
Journal:  Science       Date:  2019-08-02       Impact factor: 47.728

7.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors:  T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

8.  Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence.

Authors:  Kwinten Sliepen; Byung Woo Han; Ilja Bontjer; Petra Mooij; Fernando Garces; Anna-Janina Behrens; Kimmo Rantalainen; Sonu Kumar; Anita Sarkar; Philip J M Brouwer; Yuanzi Hua; Monica Tolazzi; Edith Schermer; Jonathan L Torres; Gabriel Ozorowski; Patricia van der Woude; Alba Torrents de la Peña; Mariëlle J van Breemen; Juan Miguel Camacho-Sánchez; Judith A Burger; Max Medina-Ramírez; Nuria González; Jose Alcami; Celia LaBranche; Gabriella Scarlatti; Marit J van Gils; Max Crispin; David C Montefiori; Andrew B Ward; Gerrit Koopman; John P Moore; Robin J Shattock; Willy M Bogers; Ian A Wilson; Rogier W Sanders
Journal:  Nat Commun       Date:  2019-05-29       Impact factor: 14.919

Review 9.  Protein and Glycan Mimicry in HIV Vaccine Design.

Authors:  Gemma E Seabright; Katie J Doores; Dennis R Burton; Max Crispin
Journal:  J Mol Biol       Date:  2019-04-24       Impact factor: 5.469

Review 10.  Innovations in structure-based antigen design and immune monitoring for next generation vaccines.

Authors:  Andrew B Ward; Ian A Wilson
Journal:  Curr Opin Immunol       Date:  2020-04-22       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.